Moderna Surges 177% as mRNA Cancer Vaccine Succeeds in Late-Stage Trial
MRNA has more than doubled off its 52-week low of $22.28 on elevated volume (20× avg).
Summary
Moderna's stock closed up 177% after its personalized mRNA cancer vaccine, intismeran autogene, combined with Merck's Keytruda, met its primary endpoint in a late-stage melanoma study, preventing cancer recurrence in high-risk patients. The final session move is materially larger than the 150% gain cited earlier, and Merck rose 13% while the SPDR S&P Biotech ETF jumped 5.9%. The surge made S&P history, according to a WSJ chart. The result is being read as a broader vindication of mRNA technology after years of post-pandemic setbacks, with analysts highlighting symbolic weight beyond the two companies. The stock is now trading near its 52-week high of $176.66, up from a low of $22.28, reflecting a dramatic re-rating. This is the second major positive catalyst for Moderna this month, following the FDA approval of its mFLUSIVA flu vaccine on August 6.
At the time of this announcement, MRNA was trading at $181.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.1B. The 52-week trading range was $22.28 to $176.66. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.